Table 1.

Baseline characteristics of patients randomized to receive rosiglitazone, metformin, or glyburide

Rosiglitazone (n = 1456)Metformin (n = 1454)Glyburide (n = 1441)
Age, years56.3 ± 10.057.9 ± 9.956.4 ± 10.2
Men, n (%)811 (55.7)864 (59.4)836 (58.0)
Time since diagnosis of diabetes, n (%)
    <1 year650 (44.6)673 (46.3)637 (44.2)
    1 to 2 years759 (52.1)724 (49.8)751 (52.1)
    >2 years47 (3.2)57 (3.9)53 (3.7)
Weight, kg91.5 ± 19.791.6 ± 18.792.0 ± 20.0
Body mass index, kg/m232.2 ± 6.732.1 ± 6.132.2 ± 6.3
Systolic BP, mmHg133 ± 16133 ± 15133 ± 15
Diastolic BP, mmHg80 ± 980 ± 979 ± 9
Hypertension, n (%)1144 (78.6)1137 (78.2)1124 (78.0)
ACEi/ARB therapy, n (%)479 (32.9)486 (33.4)477 (33.1)
Fasting plasma glucose, mg/dl151.5 ± 25.8151.3 ± 25.6152.4 ± 27.3
HbA1c, %7.36 ± 0.937.36 ± 0.937.35 ± 0.92
Urine ACR geometric mean (CV %),a,b mg/g9.9 (179.5)9.3 (172.3)9.4 (174.4)
    <30 mg/g, n (%)1185 (82.9)1201 (84.9)1210 (85.5)
    ≥30 mg/g, n (%)244 (17.1)213 (15.1)205 (14.5)
    ≥300 mg/g, n (%)24 (1.7)19 (1.3)24 (1.7)
MDRD eGFR geometric mean (CV%),a,b ml/min per 1.73 m298.0 (24.6)97.1 (25.6)95.7 (27.6)
    >130 ml/min per 1.73 m2, n (%)168 (11.5)152 (10.5)131 (9.1)
    60 to 130 ml/min per 1.73 m2, n (%)(86.5)1265 (87.0)1264 (87.7)
    <60 ml/min per 1.73 m2, n (%)29 (2.0)36 (2.5)45 (3.1)
  • a Quantitative data are expressed as mean ± SD. Log-transformed data are presented as the geometric mean and the CV %, the latter obtained as 100 × (exp[SD − mean]) where SD and mean are of the log-transformed values.

  • b Denominator does not include 93 with missing ACR at baseline, or 2 with missing eGFR.